Express is supported by EU CHMP, AbbVie IL-23 inhibitor is expected to gain the second indication

▎The content team editor of WuXi AppTec On October 15, 2021, AbbVie announced that the European Medicines Agency (EMA) Committee for Human Medicines (CHMP) recommended approval of risankizumab (trade name Skyrizi) as a single agent or combined with methylamine Pterin (MTX) is used to treat active psoriatic arthritis in adults who are inadequate or intolerant to one or more anti-rheumatic drugs (DMARDs) that change the progression of the disease
.

The press release pointed out that if approved, this will be the second indication for risankizumab in the EU
.

Psoriatic arthritis is a heterogeneous, systemic inflammatory disease with hallmark manifestations in multiple systems (including joints and skin)
.

Inflammation produced by the immune system can cause joint pain, fatigue, stiffness, and cause a red scaly rash
.

Risankizumab is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit
.

IL-23 is a cytokine involved in the inflammatory process and is believed to be involved in many chronic immune-mediated diseases, including psoriasis
.

It has been approved by the US FDA and the European Union for the treatment of psoriasis
.

In addition, a phase 3 trial of risankizumab in the treatment of psoriasis, Crohn's disease, ulcerative colitis and psoriatic arthritis is ongoing
.

This positive opinion of CHMP is supported by two pivotal Phase 3 clinical trials
.

The results of the trial showed that compared with placebo, risankizumab reached the primary endpoint of ACR20 response (20% improvement in joint swelling and tenderness) at week 24
.

In addition, risankizumab also reached several secondary endpoints, including the improvement of several clinical manifestations of psoriatic arthritis, such as skin clearance (PASI 90), physical function (HAQ-DI), and minimum disease activity at week 24 ( MDA)
.

In terms of safety, the most common adverse reactions associated with risankizumab are upper respiratory tract infections, headaches, fatigue, injection site reactions and ringworm infections
.

In addition, the efficacy and safety characteristics of risankizumab administered for up to 52 weeks are consistent with those observed at 24 weeks
.

"Although many patients with psoriatic arthritis are treated with existing therapies, their skin and joint symptoms are still not under control
.

Therefore, it is very important to provide doctors with a variety of treatment options to effectively manage the patient's condition
.

" AbbVie Senior Research and Development Vice President Thomas Hudson said, "CHMP's recommendation to approve risankizumab for the treatment of psoriatic arthritis is an important step in bringing new treatment options to more patients in need
.

"Reference: [1] AbbVie Receives CHMP Positive Opinion for Risankizumab (Skyrizi®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU).
Retrieved October 15, 2021, from https://news.
abbvie.
com/news/press-releases/abbvie-receives-chmp-positive-opinion-for-risankizumab-skyrizi-for-treatment-adults-with-active-psoriatic-arthritis-in-european-union-eu.
htm Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.

This article is for information exchange purposes only.
The opinions
in the
article do not represent WuXi AppTec's position, nor do they support or oppose WuXi AppTec's views in the article .
This article is not a treatment plan recommendation
.

If you need guidance on the treatment plan, please go to a regular hospital for treatment
.